Role of the newer p53 family proteins in malignancy

[1]  B. Pützer,et al.  Role of the p53-homologue p73 in E2F1-induced apoptosis , 2000, Nature Genetics.

[2]  David I. Smith,et al.  Role for the p53 homologue p73 in E2F-1-induced apoptosis , 2000, Nature.

[3]  A. Levine,et al.  Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73* , 2000, The Journal of Biological Chemistry.

[4]  R. Young,et al.  Biomedical Discovery with DNA Arrays , 2000, Cell.

[5]  S. Chi,et al.  Frequent alteration of p63 expression in human primary bladder carcinomas. , 2000, Cancer research.

[6]  P. Beighton,et al.  Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. , 2000, American journal of human genetics.

[7]  J. Jen,et al.  Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma , 2000, International journal of cancer.

[8]  G. Melino,et al.  Induction of Neuronal Differentiation by p73 in a Neuroblastoma Cell Line* , 2000, The Journal of Biological Chemistry.

[9]  W. Kaelin,et al.  p63 and p73: old members of a new family. , 2000, Biochimica et biophysica acta.

[10]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[12]  A. Hoffman,et al.  Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens. , 2000, Biochimica et biophysica acta.

[13]  A. Jochemsen,et al.  Physical Interaction between Wilms Tumor 1 and p73 Proteins Modulates Their Functions* , 2000, The Journal of Biological Chemistry.

[14]  R. Berkowitz,et al.  Analysis of p73 in human borderline and invasive ovarian tumor , 2000, Oncogene.

[15]  G. Yang,et al.  Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. , 2000, Carcinogenesis.

[16]  A. Yang,et al.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.

[17]  Jye-Yee Lin,et al.  Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein , 2000, Oncogene.

[18]  F. Speleman,et al.  Mutation analysis of P73 and TP53 in Merkel cell carcinoma , 2000, British Journal of Cancer.

[19]  Hua Lu,et al.  The N-Terminal Domain of p73 Interacts with the CH1 Domain of p300/CREB Binding Protein and Mediates Transcriptional Activation and Apoptosis , 2000, Molecular and Cellular Biology.

[20]  F. Carey,et al.  Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. , 2000, Carcinogenesis.

[21]  W. Kaelin.  The p53 gene family , 1999, Oncogene.

[22]  K. Kinzler,et al.  Identification and classification of p53-regulated genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Nakagawara,et al.  p53 family genes: structural comparison, expression and mutation , 1999, Cell Death and Differentiation.

[24]  J. Roth,et al.  Failure of viral oncoproteins to target the p53-homologue p51A. , 1999, The Journal of general virology.

[25]  H. Ito,et al.  Mutation and transcription analyses of the p63 gene in cervical carcinoma. , 1999, International journal of oncology.

[26]  G. Melino,et al.  Structure, function and regulation of p63 and p73 , 1999, Cell Death and Differentiation.

[27]  David I. Smith,et al.  p73 mutations are not detected in sporadic and hereditary breast cancer , 1999, Breast Cancer Research and Treatment.

[28]  Michael Bamshad,et al.  Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.

[29]  H. Yokozaki,et al.  Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype , 1999, International journal of cancer.

[30]  C. Harris,et al.  Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. , 1999, Cancer research.

[31]  C. Arrowsmith,et al.  Solution structure of a conserved C‐terminal domain of p73 with structural homology to the SAM domain , 1999, The EMBO journal.

[32]  G. Chenevix-Trench,et al.  Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target , 1999, Oncogene.

[33]  C. Garbe,et al.  Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines , 1999, International journal of cancer.

[34]  A. Harris,et al.  MDM2 and MDMX bind and stabilize the p53-related protein p73 , 1999, Current Biology.

[35]  C. Bartram,et al.  Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. , 1999, Blood.

[36]  D. Fisher,et al.  p53 and cancer therapy: a double-edged sword. , 1999, The Journal of clinical investigation.

[37]  N. L. Thangue,et al.  Promoter specificity and stability control of the p53-related protein p73 , 1999, Oncogene.

[38]  J. Herman,et al.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.

[39]  K. Vousden,et al.  Mdm2 binds p73α without targeting degradation , 1999, Oncogene.

[40]  K. Engeland,et al.  Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. , 1999, Journal of the National Cancer Institute.

[41]  Y. Ishikawa,et al.  The expression of p73 is increased in lung cancer, independent of p53 gene alteration , 1999, British Journal of Cancer.

[42]  B. Clurman,et al.  P73 mutations and expression in adult de novo acute myelogenous leukemia , 1999, Leukemia.

[43]  U. Moll,et al.  Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. , 1999, Cancer research.

[44]  Jijie Gu,et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.

[45]  S. Kato,et al.  Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer , 1999, Oncogene.

[46]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[47]  Reuven Agami,et al.  Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.

[48]  Yohko Nakamura,et al.  Mutational analysis of the p73 Gene in human breast cancers , 1999, International journal of cancer.

[49]  S. Kato,et al.  The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. , 1999, Cancer research.

[50]  A. Nakagawara,et al.  Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. , 1999, Cancer research.

[51]  S. Chi,et al.  Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer. , 1999, Cancer research.

[52]  P. Kogner,et al.  Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development. , 1999, International journal of molecular medicine.

[53]  K. Engeland,et al.  Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver , 1999, British Journal of Cancer.

[54]  D. Tindall,et al.  Mutation and expression analysis of the p73 gene in prostate cancer , 1999, The Prostate.

[55]  A. Jochemsen,et al.  Distinct Regulation of p53 and p73 Activity by Adenovirus E1A, E1B, and E4orf6 Proteins , 1999, Molecular and Cellular Biology.

[56]  C. L. Cunsolo,et al.  Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastoma , 1999, Cell Death and Differentiation.

[57]  E. Salido,et al.  Mouse p73 gene maps to the distal part of chromosome 4 and might be involved in the progression of gamma-radiation-induced T-cell lymphomas. , 1999, Cancer research.

[58]  G Melino,et al.  Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ , 1999, Cell Death and Differentiation.

[59]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[60]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[61]  W. Kaelin.  The emerging p53 gene family. , 1999, Journal of the National Cancer Institute.

[62]  A. Sakurada,et al.  Infrequent somatic mutations of the p73 gene in various human cancers. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[63]  A. Look,et al.  Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. , 1999, Neoplasia.

[64]  H. Loiseau,et al.  p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas , 1999, Neuroscience Letters.

[65]  Jieyuan Jiang,et al.  Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity , 1999, Oncogene.

[66]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[67]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[68]  F. McKeon,et al.  p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent , 1999, Oncogene.

[69]  J. Pipas,et al.  Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  W. Stolz,et al.  Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas , 1998, Melanoma research.

[71]  Xinbin Chen,et al.  The potential tumor suppressor p73 differentially regulates cellular p53 target genes. , 1998, Cancer research.

[72]  N. Nomura,et al.  p73, a geme related to p53, is not mutated in esophageal carcinomas , 1998, International journal of cancer.

[73]  G. Melino,et al.  Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.

[74]  W. Kaelin,et al.  Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.

[75]  S. Swendeman,et al.  Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[76]  J. Roth,et al.  Inactivation of p53 but Not p73 by Adenovirus Type 5 E1B 55-Kilodalton and E4 34-Kilodalton Oncoproteins , 1998, Journal of Virology.

[77]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[78]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[79]  David I. Smith,et al.  Loss of imprinting and allele switching of p73 in renal cell carcinoma , 1998, Oncogene.

[80]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[81]  A. Nakagawara,et al.  Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. , 1998, International journal of oncology.

[82]  W. Liu,et al.  Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. , 1998, Genomics.

[83]  H. Kato,et al.  A second p53-related protein, p73L, with high homology to p73. , 1998, Biochemical and biophysical research communications.

[84]  J. Jen,et al.  A new human p53 homologue , 1998, Nature Medicine.

[85]  M. Herlyn,et al.  p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. , 1998, International journal of oncology.

[86]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[87]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[88]  A. Nakagawara,et al.  Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. , 1998, Cancer Research.

[89]  S. Nomoto,et al.  Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. , 1998, Cancer research.

[90]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[91]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[92]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[93]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[94]  C. Bamberger,et al.  A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.

[95]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[96]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[97]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[98]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[99]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[100]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[101]  D. Baltimore,et al.  Proline-rich sequences that bind to Src homology 3 domains with individual specificities. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[103]  Rogier Versteeg,et al.  Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N–myc amplification , 1993, Nature Genetics.

[104]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[105]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[106]  上田 佳秀.  New p73 variants with altered C-terminal structures have varied transcriptional activities , 2001 .

[107]  D. Tindall,et al.  Differential expression and allelotyping of the p73 gene in neuroblastoma. , 2000, International journal of oncology.

[108]  Y. Shaul.  c-Abl: activation and nuclear targets , 2000, Cell Death and Differentiation.

[109]  F. Carey,et al.  Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. , 2000, Carcinogenesis.

[110]  三原 基弘.  Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma , 2000 .

[111]  G Melino,et al.  Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. , 1999, Cell death and differentiation.

[112]  T. Sakai,et al.  Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. , 1999, DNA research : an international journal for rapid publication of reports on genes and genomes.

[113]  R. Agami,et al.  Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. , 1999, Nature.

[114]  J U Bowie,et al.  p53 Family members p63 and p73 are SAM domain‐containing proteins , 1999, Protein science : a publication of the Protein Society.

[115]  O. Bernard,et al.  A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein , 1997, The EMBO journal.